Literature DB >> 6608216

Anti-inflammatory effects of muramyl dipeptide in experimental models of acute inflammation.

Z Zídek, K Masek, F Sedivý.   

Abstract

Synthetic muramyl dipeptide, N-acetylmuramyl-L-alanyl-D-isoglutamine (MDP), has been tested for activity against acute inflammation. In all models employed (Bayol + Arlacel paw oedema in rats, carrageenan pleurisy in rats, and carrageenan of dextran paw oedema in mice), MDP given in admixture with the phlogistic agents significantly lowered the resulting inflammatory reaction by about 30-40%. 0.1-0.2 mg of MDP per animal was applied. The mechanism of anti-inflammatory activity of this substance remains unknown.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6608216     DOI： 10.1007/bf01966836

Source DB:  PubMed          Journal:  Agents Actions        ISSN： 0065-4299


  17 in total

1.  Correlation of structure and adjuvant activity of N-acetyl muramyl-L-alanyl-D-isoglutamine (MDP), its derivatives and analogues. Anti-adjuvant and competition properties of stereoisomers.

Authors:  A Adam; M Devys; V Souvannavong; P Lefrancier; J Choay; E Lederer
Journal:  Biochem Biophys Res Commun       Date:  1976-09-07       Impact factor: 3.575

Review 2.  Recent developments concerning muramyl dipeptide, a synthetic immunoregulating molecule.

Authors:  L Chedid; C Carelli; F Audibert
Journal:  J Reticuloendothel Soc       Date:  1979-12

Review 3.  The inflammatory mediators.

Authors:  P A Ward
Journal:  Ann N Y Acad Sci       Date:  1974       Impact factor: 5.691

Review 4.  The immunological activities of bacterial peptidoglycans.

Authors:  D E Stewart-Tull
Journal:  Annu Rev Microbiol       Date:  1980       Impact factor: 15.500

Review 5.  Muramyl peptides. Chemical structure, biological activity and mechanism of action.

Authors:  A Adam; J F Petit; P Lefrancier; E Lederer
Journal:  Mol Cell Biochem       Date:  1981-12-04       Impact factor: 3.396

6.  Evaluation of anti-inflammatory and analgesic properties of L-glutamine.

Authors:  P Jain; N K Khanna
Journal:  Agents Actions       Date:  1981-05

7.  Macrophage activation by mycobacterial water soluble compounds and synthetic muramyl dipeptide.

Authors:  S M Wahl; L M Wahl; J B McCarthy; L Chedid; S E Mergenhagen
Journal:  J Immunol       Date:  1979-06       Impact factor: 5.422

8.  Adjuvant activity of mycobacterial fractions: adjuvant activity of synthetic N-acetylmuramyl-dipeptide and the related compounds.

Authors:  I Azuma; K Sugimura; T Taniyama; M Yamawaki; Y Yamamura
Journal:  Infect Immun       Date:  1976-07       Impact factor: 3.441

9.  Effect of indomethacin on increased resistance to bacterial infection and on febrile responses induced by muramyl dipeptide.

Authors:  M Parant; G Riveau; F Parant; C A Dinarello; S M Wolff; L Chedid
Journal:  J Infect Dis       Date:  1980-11       Impact factor: 5.226

10.  Arthritis-inducing ability of a synthetic adjuvant, N-acetylmuramyl peptides, and bacterial disaccharide peptides related to different oil vehicles and their composition.

Authors:  O Kohashi; A Tanaka; S Kotani; T Shiba; S Kusumoto; K Yokogawa; S Kawata; A Ozawa
Journal:  Infect Immun       Date:  1980-07       Impact factor: 3.441
View more
  4 in total

1.  Analgesic effects of N-acetylmuramyl-L-alanyl-D-isoglutamine in decreasing the acetic acid-induced abdominal-writhing response.

Authors:  T Ogawa; S Kotani
Journal:  Infect Immun       Date:  1987-02       Impact factor: 3.441

2.  Modulation of lymphocyte activating factor activity (interleukin 1 like activity) and acute phase proteins in pertussis-induced air pouch inflammation by muramyl dipeptide.

Authors:  A D Sedgwick; R E Hooke; P Lees; S A May
Journal:  Agents Actions       Date:  1987-06

3.  Anti-inflammatory effects of LPS, MDP and FMLP on carrageenan pleurisy in the rat.

Authors:  C A Allen; D M Ferry; V S Chadwick
Journal:  Agents Actions       Date:  1994-03

4.  Treatment of experimental erosive arthritis in rats by injection of the muralytic enzyme mutanolysin.

Authors:  M J Janusz; C Chetty; R A Eisenberg; W J Cromartie; J H Schwab
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.